EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta‐Analysis

Jia Shen Goh, Sameen Sohail, Haroon Ayub, Zian Zafar Cheema, Nitish Behary Paray iD, Sanka Adikari, Ahmad Mesmar, Mohammad Atout, Abdul Rehman Qazi, Ahmad Aldalqamouni, Bilal Younas, Muhammad Atif Rauf und 8 weitere

Endocrinology, Diabetes & Metabolism · 2025-09 · 8 (5)

DOI: 10.1002/edm2.70094 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 12.09.2025. Verfasst von Jia Shen Goh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertension remains a major contributor to global cardiovascular morbidity and mortality. Aldosterone, a key hormone in blood pressure regulation, plays a significant role in hypertension pathophysiology. This has led to growing interest in aldosterone synthase inhibitors (ASIs) as a potential treatment. This meta‐analysis aims to evaluate the efficacy and safety of ASIs in managing hypertension.

Methods

A systematic search of PubMed, Google Scholar and Cochrane Central was conducted up to 13 July 2025, to identify randomised controlled trials (RCTs) evaluating ASIs in hypertensive adults. Data were analysed using RevMan version 5.4, employing random‐effects models with significance set at p < 0.05.

Results

A total of 8 RCTs were included, with a total of 2003 participants in the ASI group and 650 participants in the placebo group. ASIs significantly reduced systolic blood pressure (SBP) compared to placebo (MD: −6.01 mmHg; 95% confidence interval [CI]: −9.31 to −2.71; I 2 = 85%; p = 0.0004); diastolic blood pressure (DBP) was found to be comparable between the two groups (MD: −2.20 mmHg; 95% CI: −4.46 to 0.06; I 2 = 69%; p = 0.06). There was a significant reduction in serum aldosterone levels favouring ASI use (MD: −1.46; 95% CI: −2.76 to −0.16; I 2 = 99%; p < 0.00001). The risk of serious (RD: 0.00; 95% CI: −0.01 to 0.02; I 2 = 30%; p = 0.75) and non‐serious adverse events (RD: 0.05; 95% CI: −0.02 to 0.12; I 2 = 64%; p = 0.20) did not differ significantly between ASI and placebo groups. However, ASI use was associated with a significantly higher risk of hyperkalemia (RD: 0.04; 95% CI: 0.02 to 0.06; I 2 = 70%; p = 0.002).

Conclusion

ASIs effectively lower SBP and serum aldosterone in adults with hypertension. They appear safe overall but may increase the risk of hyperkalemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionCytochrome P-450 CYP11B2Antihypertensive AgentsEnzyme InhibitorsHumansBlood PressureRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

Cytochrome P-450 CYP11B2Antihypertensive AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Renal Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
  • Department of Medicine, North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, UK.
  • Department of Nephrology, Indus Hospital, Lahore, Pakistan.
  • Department of Nephrology, Sialkot Medical College, Lahore, Pakistan.
  • Department of Medicine, Amna Inayat Medical College, Sheikhupura, Pakistan.
  • Department of Cardiology, Somerset NHS Foundation Trust, Taunton, UK.

ORCID-Profile: Nitish Behary Paray, Ali Hasan, Maryam Shahzad, Mushood Ahmed, Raheel Ahmed

Zitieren

APA

Goh, J. S., Sohail, S., Ayub, H., Cheema, Z. Z., Paray, N. B., Adikari, S., Mesmar, A., Atout, M., Qazi, A. R., Aldalqamouni, A., Younas, B., Rauf, M. A., Khan, M. A. W., Abouayana, A., Abouayana, A. E. A., Hasan, A., Shahzad, M., Ahmed, M., Ahmed, R., & Ahmed, S. (2025). Efficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 8(5). https://doi.org/10.1002/edm2.70094

Vancouver

Goh JS, Sohail S, Ayub H, Cheema ZZ, Paray NB, Adikari S, et al. Efficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2025;8(5). doi:10.1002/edm2.70094

BibTeX
@article{Goh2025,
  author = {Goh, Jia Shen and Sohail, Sameen and Ayub, Haroon and Cheema, Zian Zafar and Paray, Nitish Behary and Adikari, Sanka and Mesmar, Ahmad and Atout, Mohammad and Qazi, Abdul Rehman and Aldalqamouni, Ahmad and Younas, Bilal and Rauf, Muhammad Atif and Khan, Muhammad Azhar Waheed and Abouayana, Aya and Abouayana, Ahmed Eid Ahmed and Hasan, Ali and Shahzad, Maryam and Ahmed, Mushood and Ahmed, Raheel and Ahmed, Saeed},
  title = {Efficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta‐Analysis},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  volume = {8},
  number = {5},
  doi = {10.1002/edm2.70094}
}
Kostenlos starten →